



KÅRE SCHULTZ, CEO
TEVA PHARMACEUTICAL INDUSTRIES LTD.



From 2015 to October 31, 2017, Mr. Schultz served as the President and Chief Executive Officer of H. Lundbeck A/S. When he joined the company in 2015, H. Lundbeck A/S was facing the loss of critical patents.

Prior to joining Lundbeck, Mr. Schultz worked for nearly three decades at Novo Nordisk, where he served in a number of leadership roles, including Chief Operating Officer, Vice President in Product Supply and Director of Product Planning and Customer Services in the Diabetes Care Division. At Novo Nordisk, Mr. Schultz played a major role in modernizing the company's large scale biologic production and leading the company's expansion into the US and Chinese markets.

In addition to his time at Novo Nordisk, Mr. Schultz has held positions at McKinsey and Anderson Consulting. In these roles, he developed a unique global perspective on the healthcare and pharmaceutical industries, expanded his deep financial acumen, demonstrated a commitment to strong compliance principles and enforcement and oversaw business operations and teams across Europe and North America and the Middle East.

Mr. Schultz serves as a member of the board of directors of International Flavors and Fragrances Inc. since February 2021. Mr. Schultz served as the Chairman of the Board of Directors of Royal Unibrew A/S, and also served as a member of the Board of Directors of LEGO A/S, and Bitten og Mads Clausens Fond, the holding vehicle for Danfoss A/S. He holds a master's degree in Economics from the University of Copenhagen.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.